HC Wainwright Reaffirms Buy Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)

HC Wainwright reaffirmed their buy rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a research report sent to investors on Tuesday morning,Benzinga reports. HC Wainwright currently has a $18.00 price objective on the biotechnology company’s stock.

Several other equities analysts have also issued reports on ENTA. Robert W. Baird cut their price objective on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, November 26th. JMP Securities reissued a “market outperform” rating and set a $21.00 price objective (down from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Two analysts have rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $17.25.

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ:ENTA opened at $5.59 on Tuesday. The firm has a market cap of $119.23 million, a PE ratio of -1.02 and a beta of 0.54. The firm’s 50 day simple moving average is $5.87 and its 200-day simple moving average is $9.61. Enanta Pharmaceuticals has a one year low of $4.71 and a one year high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. Equities research analysts predict that Enanta Pharmaceuticals will post -5.05 EPS for the current fiscal year.

Insider Transactions at Enanta Pharmaceuticals

In related news, CEO Jay R. Luly sold 5,142 shares of the business’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $8.06, for a total transaction of $41,444.52. Following the completion of the transaction, the chief executive officer now directly owns 801,638 shares in the company, valued at $6,461,202.28. The trade was a 0.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 13.89% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ENTA. AlphaQuest LLC increased its holdings in Enanta Pharmaceuticals by 16.4% in the fourth quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 3,137 shares in the last quarter. American Century Companies Inc. increased its stake in shares of Enanta Pharmaceuticals by 10.5% during the fourth quarter. American Century Companies Inc. now owns 36,962 shares of the biotechnology company’s stock worth $213,000 after purchasing an additional 3,501 shares in the last quarter. US Bancorp DE increased its stake in shares of Enanta Pharmaceuticals by 4,933.7% during the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 4,243 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Enanta Pharmaceuticals during the 4th quarter valued at about $26,000. Finally, Quest Partners LLC grew its stake in Enanta Pharmaceuticals by 65.0% during the 3rd quarter. Quest Partners LLC now owns 19,123 shares of the biotechnology company’s stock valued at $198,000 after acquiring an additional 7,535 shares in the last quarter. 94.99% of the stock is currently owned by institutional investors and hedge funds.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.